Pauling.AI
Developer of a cloud-based, AI-driven platform for end-to-end in silico drug discovery. The platform uses autonomous AI agents to design and execute computational chemistry workflows — including receptor preparation, docking, molecular dynamics, and ADMET prediction — at enterprise scale with automated quality control and large-scale compound processing.
Industries
N/A
Nr. of Employees
small (1-50)
Services
A cloud platform that accepts a biological target and executes an automated computational discovery workflow including target preparation, AI-guided design, docking, MD validation, ADMET profiling, and quality control to produce prioritized candidate molecules.
A cloud platform that accepts a biological target and executes an automated computational discovery workflow including target preparation, AI-guided design, docking, MD validation, ADMET profiling, and quality control to produce prioritized candidate molecules.
Expertise Areas
- Autonomous drug discovery
- Computational chemistry workflows
- High-throughput virtual screening
- Molecular dynamics and binding affinity estimation
Key Technologies
- Molecular dynamics
- Molecular docking
- Generative and docking AI models
- Multi-LLM agent orchestration